A story in the British Medical Journal (BMJ) debunks the claim made by American pharmaceutical companies that they charge more for their products because they spend more on research and development than firms in the rest of the world do.
In fact, the piece shows, U.K. drug companies spend proportionately more on R&D than their U.S. counterparts, but British drug prices remain much lower than those in the United States.
The BMJ article argues convincingly that in fact, American drugmakers invest three times more money on advertising, marketing, and administration than on research, and could cut costs in those areas if they truly wished to.